International Journal on Recent Researches In Science, Engineering & Technology
(Division of Computer Science and Engineering)
A Journal Established in early 2000 as National journal and upgraded to International journal in 2013 and is in existence for the last 10 years. It is run by Retired Professors from NIT, Trichy. It is an absolutely free (No processing charges, No publishing charges etc) Journal Indexed in JIR, DIIF and SJIF.
Research Paper
Available online at: www.jrrset.com

ISSN (Print) : 2347-6729
ISSN (Online) : 2348-3105

Volume 3, Issue 12, December 2015.

JIR IF : 2.54
DIIF IF : 1.46
SJIF IF : 1.329

Soaring in Vivo Platelet Motions in Woman Fibromyalgia Victims

Sharanabasaveshwar G Hiremath, C.Narayanan
Department of Biomedical Engineering
Dhanalakshmi Srinivasan Engineering College, Tamil Nadu, India

Abstract
Introduction: Fibromyalgia (FMS) is a pain syndrome characterized by way of chronic enormous pain and hyperalgesia/allodynia. Many affected are girls and chance elements are unidentified. Today, a sure quantity of set criteria of sickness signs and symptoms must be met for the diagnosis to be made. These criteria are used because of the lack of dependable biomarkers or different scientific examination. The present day find out about examines if in vivo platelet pastime varies between FMS and controls besides FMS.
Keywords: Platelet activity; Platelet heterogeneity; Fibromyalgia; Fibrinogen; Platelets

Introduction

Fibromyalgia syndrome (FMS) is a persistent ache syndrome [1] associated with several symptoms including; pain, fatigue, sleep problems, depression, digestive problems, intestinal issues and anxiety [2]. In 1990, the American College of Rheumatology (ACR) set up the now normally used criteria for FMS. ACR agreed that sufferers must have tremendous ache in aggregate with huge pain hypersensitivity for mechanical pressure, which is captured the usage of manual palpation in at least 11 of 18 standardized anatomical areas (tender points) [1,3]. FMS is an unbiased prognosis everyday through the World Health Organization (WHO). The population occurrence of FMS in the western world is 2-4% and it influences female extra regularly than men. It typically begins as a neighborhood pain condition which spreads thru the body over time; the threat factors for this spreading are on the whole unknown [4]. Pain medicine lacks objective biomarkers to guide the analysis and preference of treatment. Hence, there is a lack of reliable and objective blood exams (biomarkers) that can be used as a part of the medical assessment of patients that fulfill the ACR criteria of FMS. As ache by way of definition is a subjective ride it has been pointed out that biomarkers for pain are impossibility [5]. Bäckryd has proposed that "nocimarker" would be a better time period than pain biomarker for denoting attempts to discover objective, measurable correlates to the neurobiological strategies involved in unique pain prerequisites [6]. FMS is associated with central differences (e.g. central hyperexcitability with disinhibition and per chance facilitation of nociceptive afferent activity) [7]. However, controversies exist regarding the position of peripheral elements e.g. peripheral nociceptive inputs, muscle, and nociceptive C-fibre alterations and systematic ameliorations for keeping central mechanisms [8]. Blood-including the subcomponents serum and plasma reflects systemic aspects. Serum serotonin tiers had been drastically decrease in FMS as in contrast to manipulate people [9]. Behm and Associates investigated the immune role, especially mononuclear mobile cytokine manufacturing in FMS and said lower levels of IL-5, IL-6, IL-8, IL-10 and IFN-γ [10]. Other studies have also said alterations

in the signature of cytokines in FMS [11,12]. Another study examined the peripheral benzodiazepine receptors on the leukocyte surface.

There used to be an accelerated level of the receptors in monocytes [13]. Recently our group suggested substantially extended plasma levels of lactate and glutamate in a cohort of continual good sized ache (mainly FMS; 15 out of 17 subjects) [8]. There are very few research related to platelets elements in FMS. Nevertheless, platelets accumulated from FMS patients had elevated degrees of magnesium and lower tiers of adenosine triphosphate, in evaluation with controls [14]. In complete blood, platelets are the smallest corpuscular body. They range in density within the span of 1.04–1.08 kg/l [15,16]. Platelet organelles are key determinants of density; high-density cells have more α and dense granules [15]. In some studies, it has been mentioned that platelet density will increase as they get older [17,18], whereas other studies have come to the contrary view [19,20]. Furthermore, different scientists take the view that platelet density does no longer change in the circulation [21-23]. The clinical impact of platelet heterogeneity has been investigated for a long length of time. Platelet density is accelerated in conjunction with acute myocardial infarctions (AMI) [24]. ST-elevation AMI is similarly characterized through an inverse relationship between density and the inflammatory response [25]. The endeavor of inflammatory bowel ailment is linked to small high-density platelets [26]. Low peak platelet density characterizes vital thrombocythemia [27] and preeclampsia severity is associated with giant platelets having low top density [28]. The study about objectives to inspect if platelet in vivo exercise differs in FMS in contrast to a manipulate group (CON) besides FMS. Material and Methods Subjects The learn about was approved by way of the neighborhood ethics committee of Linköping University, Sweden (reg. number: 2012/269-32). All contributors gave knowledgeable consent. 24 female sufferers affected through FMS, aged 38 ± 9 years (mean ± SD) participated in the study. All FMS topics have been enrolled for this learn about from sufferers looking for care at the Pain and Rehabilitation Centre of the University Hospital, Linköping, Sweden. Patients pleasant the criteria of the American College of Rheumatology standards for FMs have been covered in the find out about [1]. The clinical diagnoses of FMS had been retrospectively proven from the patient's case histories and medical examinations. 25 healthful females aged 50 ± 12 years (mean ± SD) had been used as a CON. All of the CON group have been enrolled in the learn about when visiting a close by clinical core for an everyday activities check. Table 1 summarizes scientific information at the time of entry to the study. Table 1 Demographic statistics and pharmacological remedies at study inclusion for fibromyalgia syndrome sufferers (FMS) and controls (CON).

Laboratory investigations

All blood samples have been accumulated in Vacutainer™ tubes (Becton and Dickinson, New Jersey, USA.). Venous blood (7.5 mL) was once anticoagulated with 2.5 mL 0.129 M disodium citrate. In order to separate platelets according to density, a linear Percoll™ (GE Healthcare Bio-Sciences AB, Sweden) gradient used to be used [29,30]. The following materials had been combined in order to furnish the two Percoll™ solutions (1.09 and 1.04 kg/L) for the gradient (Table 2). Table 2 List of Solutions.

PercollTM solutions	1.09 kg/L	1.04 kg/L
H_2O	11.42 g	19.14 g
PercollTM	32.84 g	8.88 g

Table 1 Demographic data and pharmacological treatments at study inclusion for fibromyalgia syndrome patients (FMS) and controls (CON).

	FMS	CON	p-value
Subjects (n)	24	25	
Gender (male/female)	0/24	0/25	
Age (years)	38 ± 9	50 ± 12	NS
Body mass index (kg/m^2)	28 ± 7	23 ± 3	$p < 0.05$
Diabetes (n)	0	0	NS
A2-blockers (n)	0	2	NS
ACE-inhibitors (n)	2	3	NS
Acetaminophen (n)	18	0	$p < 0.05$
Antidepressant (n)	22	0	$p < 0.05$
β-blockers (n)	1	5	NS
Ca^{2+}-blockers (n)	0	6	NS
Diuretics (n)	0	5	NS
NSAID (n)	11	0	$p < 0.05$
Statins (n)	0	3	NS
Vitamin B12 (n)	1	0	NS

To avoid in vitro platelet activity, the PercollTM solutions contained a platelet inhibitory solution (Na3EDTA and prostaglandin E1).

A two-chamber gradient maker was used to produce linear gradients. The gradients were manufactured in 50 mL test tubes covering the density span of 1.09 kg/L to 1.04 kg/L. 7.63 g of the 1.09 kg/L PercollTM mixture was layered in the bottom of the test tube. Then, 13.08 g of the 1.09 kg/L and 12.48 g of the 1.04 kg/L PercollTM solutions have been employed into two-chamber gradient makers to make the gradient. Subsequently, 10 mL citrate anticoagulated total blood was once carefully layered on pinnacle of a 50 mL check tube with the completely produced gradient. The tube was thereafter centrifuged at 2767 g for 1½ hours. After centrifugation, the underside of the check tube was once punctured and the contents had been separated via gravity into 17 specific density fractions [30]. By this setting, each and every fraction holds about 2 mL of the take a look at tube content. Platelet counts were decided in all fractions the usage of a CELL-DYN 4000 (Abbott Diagnostics, Illinois, USA). Platelet-bound fibrinogen (%) were additionally measured in each fraction with a Beckman Coulter EPICS XL-MCLTM Flow Cytometer (Beckman Coulter, Inc., California, USA). Platelets were recognized with a PE-conjugated antibody in opposition to GPIb (Dako AS, Denmark). A FIT conjugated poultry antihuman fibrinogen polyclonal antibody (Biopool AB, Sweden) discriminated membrane-bound fibrinogen [31]. As no agonist was delivered platelet-bound fibrinogen in this setting mirrors in vivo platelet activity.

Statistics

Microsoft Excel® was once used for statistical evaluations. In textual content and tables are mentioned suggest values ± one widespread deviation (SD). The unpaired Student's t-test was employed for evaluating quantitative data. p-values ≤ 0.05 had been regarded to indicate significance.

Results

Background information

No full-size distinction in age was once determined (Table 1). The Body Mass Index (BMI) was greater in FMS than in CON (p < 0.05) (Table 1). Except for demographic data, Table 1 also indicates as expected differences in medicinal drug the place the most high-quality used to be the differences in consumption regarding Acetaminophen, Antidepressant and NSAID drug treatments (p < 0.05).

Laboratory data

The distribution of platelets in the 17 density fractions is tested in Figure 1. There used to be no difference between the groups. Figure 2 indicates in vivo platelet undertaking i.e. p.c fibrinogen sure platelets in 17 exclusive density fractions. FMS compared to the CON, showed drastically greater fibrinogen bound platelets in most of the platelet density fractions. Especially, numbers 2-14 and 16 displayed drastically higher platelet in vivo undertaking (p < 0.05). In contrast, the platelet from fractions (numbers 1, 15 and 17) did not flow into activated in FMS (Figure 2).



Figure 1 The distribution of platelets (×109/L) in the gradient for FMS patients and controls. Fraction no. 1 contains platelets having the highest density and fraction no. 17 contains platelets having the lowest density.



Figure 2 Platelet bound fibrinogen (%) i.e. in vivo platelet activity, is shown for FMS patients and healthy controls. The densest platelets are found in fraction no. 1 and the lightest in fraction no. 17.

Discussion

The modern-day learn about indicates that FMS is characterised by using tremendous differences in the heterogeneity of in vivo circulating platelets. Indeed, compared with controls FMS sufferers showed a higher in vivo platelet endeavor i.e. platelet-bound fibrinogen. To the high-quality of our knowledge, this is the first file investigating FMS with recognize to platelet-bound fibrinogen in distinctive platelet density subpopulations. One can expect that the cutting-edge method has a number of weaknesses. One of these is the preanalytical impact on platelet activation. It can likely be viewed that if platelets are treated as described it is impossible to avoid an activation of the platelets, which will affect the effects obtained. However our opinion is that the effect is comparable in the two groups, i.e. we have dealt with and performed all analyzes in exactly the identical way on each character in both groups.

If the activation of the platelets had took place in the preanalytical process, it had took place in both groups. In any case, the result suggests a extensive distinction whether a preanalytical activation has regarded or not. A cautious conclusion that we can draw from our findings is that the disorder is related to in vivo activated platelets. It is additionally properly recognized that platelet characteristic is affected via antiplatelet tablets in the body. However, some humans showcase robust reactions whilst others only have vulnerable platelet inhibition. Earlier research have proven that individual variant exists when this drug is given [32]. In the present day learn about none of the controls received any anti-platelet drugs, still, it is proposed that NSAID capsules affect platelet aggregation to varying levels [33]. In the present day study, eleven of the FMs did get hold of NSAID. It is feasible that the drug influenced the effects of platelet fibrinogen binding (Figure 2). One can postulate that without NSAID FMS would have an even greater percentage of platelet fibrinogen binding. Also, it is established that platelet exercise measurements can rely on the platelet number, nevertheless, platelet distribution (Figure 1) was comparable in both groups, i.e., no differences were found between the groups. For this reason, we do not see the platelet remember as an necessary element that ought to have affected our acquired results. The most important criticism of this learn about is possibly that we have no longer chosen an age-matched control group. Obviously, there is a distinction in age between both groups, however no longer significant.

The control team consists of some older individuals. It is alternatively very hard to comment on whether the age of sufferers alters platelet activity. There are no studies that assist the latter. We have assumed that the age distinction between the agencies no longer affect platelets. Moreover, for obvious reasons we only chosen female in the manipulate crew due to the fact the FMS crew consisted of women. The existing approach used in this work is tremendously simple to perform, for that reason, it must be viable to use the approach as a supportive diagnostic tool in the clinical examination of sufferers with widespread pain. However, it is important to verify the current effects in other cohorts of FMS. It is also vital to check out if the finding of activated platelets is unique for FMS or could be connected to continual pain of special etiologies. The scientific magnitude of the observed platelet heterogeneity i.e. activated in vivo platelets stays unclear; consisting of what may be the foundation and consequence of disparities. One cannot choose the clinical relevance of our findings based on the existing study. For this reason, it is important to make similarly tries to look into why the platelets are activated in FMS and in such studies consist of assessments of co-morbidities.

Conflict of Interest Statement

We declare that no financial relationships exists that can be construed as a warfare of interest.

References

[1] Wolfe, Frederick, et al. "The American College of Rheumatology 1990 criteria for the classification of fibromyalgia." Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 33.2 (1990): 160-172.
[2] Hudson JI, Goldenberg DL, Pope HG Jr, Keck PE Jr, Schlesinger L (1992) Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med 92: 363-367.
[3] Mease P (2005) Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl 75: 6-21.
[4] Larsson B, Björk J, Börsbo B, Gerdle B (2012) A systematic review of risk factors associated with transitioning from regional musculoskeletal pain to chronic widespread pain. Eur J Pain 16: 1084-1093.
[5] Kalso, Eija. "Biomarkers for painSee related article by Eisenach et al., pages 207–212 of this issue." (2004): 199-201.
[6] Bäckryd, E. "Pain and consciousness mocks philosophers and scientists." Lakartidningen 109.20-21 (2012): 1039.
[7] Cagnie, Barbara, et al. "Central sensitization in fibromyalgia? A systematic review on structural and functional brain MRI." Seminars in arthritis and rheumatism. Vol. 44. No. 1. WB Saunders, 2014.
[8] Gerdle, Björn, et al. "Chronic widespread pain: increased glutamate and lactate concentrations in the trapezius muscle and plasma." The Clinical journal of pain 30.5 (2014): 409-420.
[9] Wolfe, F., et al. "Serotonin levels, pain threshold, and fibromyalgia symptoms in the general population." The Journal of rheumatology 24.3 (1997): 555-559.
[10] Behm, Frederick G., et al. "Unique immunologic patterns in fibromyalgia." BMC clinical pathology 12.1 (2012): 25.
[11] Üçeyler, Nurcan, Winfried Häuser, and Claudia Sommer. "Systematic review with meta-analysis: cytokines in fibromyalgia syndrome." BMC musculoskeletal disorders 12.1 (2011): 245.
[12] Sturgill, Jamie, Elizabeth McGee, and Victoria Menzies. "Unique cytokine signature in the plasma of patients with fibromyalgia." Journal of immunology research 2014 (2014).
[13] Faggioli, P., et al. "Increase in peripheral benzodiazepine receptors on monocytes in fibromyalgia." Rheumatology 43.10 (2004): 1224-1225.
[14] Bazzichi, Laura, et al. "ATP, calcium and magnesium levels in platelets of patients with primary fibromyalgia." Clinical biochemistry 41.13 (2008): 1084-1090.
[15] Chamberlain, K. G., et al. "Morphometric analysis of density subpopulations of normal human platelets." Thrombosis and haemostasis 60.01 (1988): 044-049.
[16] Chamberlain, K. G., and D. G. Penington. "Monoamine oxidase and other mitochondrial enzymes in density subpopulations of human platelets." Thrombosis and haemostasis 59.01 (1988): 029-033.
[17] Mezzano, Diego, et al. "Evidence that platelet buoyant density, but not size, correlates with platelet age in man." American journal of hematology 11.1 (1981): 61-76.
[18] Boneu, B., et al. "Further studies on the relationship between platelet buoyant density and platelet age." American journal of hematology 13.3 (1982): 239-246.
[19] Karpatkin, Simon. "Heterogeneity of human platelets: II. Functional evidence suggestive of young and old platelets." The Journal of clinical investigation 48.6 (1969): 1083-1087.

[20] Corash, Laurence, Henry Tan, and Harvey R. Gralnick. "Heterogeneity of human whole blood platelet subpopulations. I. Relationship between buoyant density, cell volume, and ultrastructure." Blood 49.1 (1977): 71-87.
[21] Penington, D. G., et al. "Platelet density and size: the interpretation of heterogeneity." British journal of Haematology34.3 (1976): 365-376.
[22] Caranobe, C., P. Sie, and B. Boneu. "Serotonin uptake and storage in human platelet density subpopulations." British journal of haematology 52.2 (1982): 253-258.
[23] Martin, J. F., et al. "Measurement of the density of human platelets and its relationship to volume." British journal of haematology 54.3 (1983): 337-352.
[24] Martin, J. F., et al. "Changes in volume and density of platelets in myocardial infarction." Br Med J (Clin Res Ed) 287.6390 (1983): 456-459.
[25] Järemo, Petter, G. Hansson, and O. Nilsson. "Elevated inflammatory parameters are associated with lower platelet density in acute myocardial infarctions with ST-elevation." Thrombosis research 100.6 (2000): 471-478.
[26] Järemo, P., and H. Sandberg-Gertzen. "Platelet density and size in inflammatory bowel disease." Thrombosis and haemostasis 76.04 (1996): 560-561.
[27] Jaremo, P. "Platelet density in essential thrombocythemia and polycythemia vera." Platelets 10.1 (1999): 61-63.
[28] Järemo, Peter, et al. "The use of platelet density and volume measurements to estimate the severity of pre- eclampsia." European journal of clinical investigation 30.12 (2000): 1113-1118.
[29] Järemo, Petter. "Computerised method for recording platelet density distribution." European journal of haematology 54.5 (1995): 304-309.
[30] Milovanovic, Micha, et al. "Platelet density distribution in essential thrombocythemia." Pathophysiology of haemostasis and thrombosis 37.1 (2010): 35-42.
[31] Lindahl, Tomas L., Roger Festin, and Anders Larsson. "Studies of fibrinogen binding to platelets by flow cytometry: an improved method for studies of platelet activation." Thrombosis and haemostasis 68.02 (1992): 221-225.
[32] Järemo P, Lindahl TL, Fransson SG, Richter A (2002) Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 252: 233-238.
[33] Cronberg, S., E. Wallmark, and I. Söderberg. "Effect on platelet aggregation of oral administration of 10 non- steroidal analgesics to humans." Scandinavian journal of haematology33.2 (1984): 155-159.